Measuring Biological Age: From PAI-1 to a Clinically Practical PCAge Score

Chronological age is a blunt instrument. It correlates with disease risk on average, but averages obscure exactly the women this magazine writes for — the ones whose lab values, family histories and daily lives diverge sharply from the curve. Researchers have spent the last decade trying to build a better ruler: biological-age estimators that combine biomarkers into a single number meant to reflect how worn, inflamed or metabolically taxed a body actually is.

Most of those estimators have lived in research labs, requiring epigenetic assays or proteomic panels that a typical clinic can't order. A 2025 paper in GeroScience takes a deliberately humbler approach: build the score from things your doctor already measures. The authors developed PCAge using common clinical, physiological and laboratory indices routinely collected in primary healthcare, drawing on the China Health and Retirement Longitudinal Study (CHARLS). The result correlated tightly with chronological age — r = 0.86 to 0.88 — which is the floor any credible age estimator has to clear before its deviations from chronology mean anything.

The more interesting number is what happens when biological and chronological ages diverge. In the CHARLS analysis, participants whose PCAge ran ahead of their chronological age carried a meaningfully higher risk of age-related disease, including cardiovascular disease with a hazard ratio of 1.30. A hazard ratio of 1.30 is not a thunderclap; it is a steady, consistent signal that the people the model flagged as biologically older were, in fact, getting sicker faster.

That nuance matters. A score like PCAge isn't a verdict, and it isn't a diagnosis. It's a way to sort a population — or, eventually, a clinic's panel of patients — into groups whose risk warrants closer attention. For a 60-year-old woman whose PCAge reads 66, the useful question isn't "how do I lower my PCAge?" It is "which of the inputs feeding that score — blood pressure, glucose handling, kidney function, inflammation — is doing the most to push it up?"

If PCAge is a population-level lens, plasminogen activator inhibitor-1 — PAI-1 — is a molecular one. PAI-1 has long been known as a regulator of fibrinolysis, the system that keeps blood clots from getting out of hand. But a 2025 review in The Journal of Cardiovascular Aging argues its job description is much broader. The authors describe PAI-1 as a protein that mediates vascular stiffness, cellular senescence and immune evasion — three processes that sit close to the heart of why cardiovascular systems age the way they do.

Senescent cells, the so-called zombie cells that stop dividing but refuse to die, secrete a cocktail of inflammatory signals into surrounding tissue. PAI-1 is part of that cocktail, and it appears to reinforce the senescent state — a feedback loop that may help explain stiffening arteries and a fatigued heart muscle. The review frames PAI-1 as a candidate therapeutic target, suggesting that targeting PAI-1 could provide a promising strategy to mitigate age-related cardiovascular disease, with particular attention to extracellular matrix remodeling and senescence signaling.

The word to underline is could. This is a mechanistic and translational review, not a phase-three trial. PAI-1 inhibitors exist in research pipelines; they are not in your pharmacy.

Both of these papers earn a measured response. PCAge was developed in a single national cohort; replication in other populations — including Western, more ethnically diverse and longitudinally deeper datasets — is the next test. A model that performs beautifully in CHARLS may need recalibration before it can be trusted in a clinic in Boston or Berlin. The PAI-1 story is earlier still: a coherent mechanistic case, supported by years of biology, that has not yet produced an approved therapy for cardiovascular aging.

This is the honest middle of biological-age research right now. It is no longer fringe; it is not yet routine. The direction of travel — toward tools that a primary-care clinician can actually use, and toward targets that drug developers can actually drug — is encouraging, and worth following without getting ahead of the data.

Neither paper changes what a thoughtful midlife checkup looks like. The inputs PCAge relies on — blood pressure, glucose, kidney markers, inflammatory signals — are the same numbers a good clinician already pays attention to. The shift these tools promise is interpretive: a way to combine them into something more meaningful than a list of values inside or outside reference ranges. If your next physical produces a stack of "normal" labs that nonetheless leaves you uneasy, that is a reasonable conversation to bring to your doctor. So is a frank discussion of cardiovascular risk that goes beyond a single LDL number.

Biological age, in other words, is becoming a more honest mirror. It is not a crystal ball, and the women this magazine serves have heard enough crystal-ball promises to last several lifetimes. What the 2025 literature offers instead is something quieter and more useful: better questions, asked of the body you actually have.